[Application of the system for rheolytic thrombectomy in patients with acute myocardial infarction].
The authors present first experience of application of the system for rheolytic therapy AngioJet in a group of patients with acute myocardial infarction. They describe principle of the work of rheolytic systems, possible procedure related complications. They also discuss results of clinical studies analyzing efficacy of antithrombotic therapy, efficacy and safety of rheolytic therapy in patients with acute coronary syndrome and complicated atherosclerotic plaques in coronary arteries.
Ardashev
A V
AV
Shavarov
A A
AA
Konev
A V
AV
Rybachenko
M S
MS
Kriuchko
M V
MV
Vrublevskiĭ
O Iu
OIu
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D004867:Equipment Design; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011859:Radiography; D012720:Severity of Illness Index; D017131:Thrombectomy / Q000295:instrumentation*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab